Myovant Sciences, a biopharmaceutical company focused on the innovative treatment of endocrine diseases, has secured flexible financing commitments of up to $140m from NovaQuest Capital Management and Hercules Capital, Inc. The proceeds from both financings will be used to fund the ongoing Phase 3 development of Myovant’s lead compound “relugolix”.
VISCHER advised Myovant as Swiss counsel. The team included Dr. Adrian Dörig (Partner, Corporate), Christoph Niederer (Partner, Tax), Sebastian Flückiger (Associate, Corporate), Ruben Masar (Associate, Corporate) and Seraina Tsering (Associate, Corporate ).
The post Financing of Myovant Sciences appeared first on The Lawyer | Legal News and Jobs | Advancing the business of law.